Enesi Pharma is to collaborate with the U.S. Biomedical Advanced Research and Development Authority's DRIVe (Division of Research, Innovation, and Ventures) on an initiative to use Enesi's ImplaVax® device and formulation technology not only to develop new vaccines against influenza, but to provide a cost-effective technological innovation that improves vaccination uptake, coverage, compliance and preparedness. ImplaVax® could become a potentially disruptive technology not only for pandemic influenza, but for multiple vaccines, vaccination protocols, infectious diseases and biological threats.
“Enesi Pharma to partner BARDA DRIVe on revolutionising vaccine delivery. “
Enesi chief executive officer, David Hipkiss, said: "We are extremely proud to have been selected by BARDA DRIVe for this partnership. The team at DRIVe has been incredibly supportive of Enesi and clearly recognize the need to revolutionize vaccine delivery as part of their mission to advance research and development of medical countermeasures against serious health security threats. This is the latest in a series of key strategic partnerships and represents the next step in our journey to make a tangible difference to global healthcare."